Table 3.

Summary of the Outcomes of Interest of the Included Studies without a Relevant Comparison of TBP vs. Non-TBP.

Study	Biopsies				Melanoma Cases				Benign-to-Malignant Ratio	Mean/Median Breslow Index
	Numbers	Due to TBP	Due to Change of Existing /Tracked Lesion	Due to Newly Emerged Lesion	Number	Due to TBP	Due to Change of Existing /Tracked Lesion	Due to Newly Emerged Lesion
Prospective Trials
Banky 2005	n.r.	n.r.	n.r.	n.r.	18 (19 per 1000 patient-year)	n.r.	n.r.	n.r.	3:1	0.39 mm
Goodson 2010	548 in 1076 patients (0.51 biopsies per patient) 273 at initial visit 275 at follow-up	168	148 of 275	20 of 275	16 at initial visit (invasive 8) 12 at follow-up (invasive 5)	n.r.	5	2	n.r.	At initial visit: median 0.39 average 0.83 mm range 0.25–>3mm At follow-up: median 0.36 mm average 0.38 mm range 0.19–0.65 mm
Kelly 1997	210	n.r.	n.r.	n.r.	20 melanomas in 16 patients (in situ 8; invasive 12)	11	n.r.	n.r.	n.r.	Median 0.40 mm
Moloney 2014	n.r.	n.r.	n.r.	n.r.	75 primary melanoma (82 absolute) 14 at baseline 61 at post-baseline	23	n.r.	n.r.	4.4:1	Median Breslow: in situ (range in situ to 0.60 mm)
Nathansohn 2007	236	n.r.	n.r.	n.r.	7	n.r.	n.r.	n.r.	n.r.	n.r.
Salerni 2012	1152 in 407 patients (mean 1.86 lesions per patient)	n.r.	n.r.	n.r.	98 in 78 patients (8.5% of excised lesions); (in situ 53)	n.r.	60	38	Monitored lesions: 11.9:1 New lesions: 8.8:1	Median 0.5 mm
Retrospective Studies
Drugge 2019	268 biopsies in 218 patients	n.r.	n.r.	n.r.	65 in 218 patients (in situ 39; invasive 26) In situ/ invasive ratio 1.56:1	n.r.	n.r.	n.r.	3.1:1	n.r.
Drugge 2020	225 biopsies in 218 patients	n.r.	149 of 225	76 of 225	67 of 225 biopsies (in situ 44; invasive 23)	n.r.	n.r.	n.r.	n.r.	Median 0.30 mm (range 0.12–0.65 mm)
Feit 2004	77 melanocytic lesions (93 in total)	n.r.	47	27	27 in 12 patients (in situ 21; invasive 6)	n.r.	20	5	n.r.	Absolut values of tumors: 0.2 mm/0.25 mm/0.25 mm/0.35 mm /0.9 mm/1.1 mm